ClinicalTrials.gg
Active, not recruitingNCT04442022Updated Oct 2, 2026

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

A Phase 2/3 interventional study of Selinexor (combination therapy) and Selinexor (combination therapy) in Relapsed/Refractory Diffuse Large B-cell Lymphoma, sponsored by Karyopharm Therapeutics Inc. Active, not recruiting at 38 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Karyopharm Therapeutics Inc · Phase 2/3, Interventional, and Treatment

Updated Oct 2, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
501
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing selinexor in Lymphoma, Large B-Cell, Diffuse — 1 open to participants now, 4 under way, 1 of them phase 3. selinexor · Lymphoma, Large B-Cell, Diffuse.

Planned enrollment
Largest of 11
501 · median 54
Started
2020
with 1 other
Phase 2/3
Only one
of the 11
Registered
7th of 11
by date
Lead sponsor
2 of 11
Karyopharm Therapeutics Inc

Among the 11 studies testing selinexor in Lymphoma, Large B-Cell, Diffuse, this one has the largest planned enrollment, is one of 2 that started in 2020, is the only one in phase 2/3, and was the 7th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 357 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

1 of the 11 studies testing selinexor in Lymphoma, Large B-Cell, Diffuse is open now. Recruiting first, the newest first:

About selinexor

selinexor: first FDA approval 2019 (XPOVIO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing selinexor in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen receptor T cell (CAR-T) therapy. This study consists of 3 arms each in Phase 2 and 3. Phase 2 portion of the study will assess the two doses of selinexor (40 milligram [mg] or 60 mg) in combination with R-GDP, for up to 6 cycles (21-day per cycle), followed by 60 mg selinexor single agent continuous therapy for those who have reached a partial or complete response. Phase 3 portion of the study will evaluate the selected dose of SR-GDP (identified in Phase 2) versus standard R-GDP + matching placebo, for up to 6 cycles (21-day per cycle), followed by placebo or 60 mg selinexor single agent continuous therapy for those who have reached partial or complete response.

03

Conditions studied

  • Relapsed/Refractory Diffuse Large B-cell Lymphoma

Keywords

  • Relapsed/Refractory DLBCL
  • Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP)
  • Selinexor
  • Karyopharm
  • KCP-330
  • XPOVIO
  • DLBCL
  • XPORT-DLBCL-030
  • R-GDP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have confirmed de novo DLBCL or DLBCL transformed from previously diagnosed indolent lymphoma (e.g., follicular lymphoma). Patient with high-grade lymphoma with c-MYC, Bcl2 and/or Bcl6 rearrangements are eligible (only for Phase 2). (Documentation to be provided).
  • Have received at least 1 but no more than 3 for the treatment of DLBCL with disease following their most recent regimen.

    • Salvage chemoimmunotherapy followed by stem cell transplantation will be considered as 1 line of systemic therapy.
    • Maintenance therapy will not be counted as a separate line of systemic therapy.
    • Radiation with curative intent for localized DLBCL will not be counted as 1 line of systemic therapy.
  • Positron emission tomography (PET) positive with at least 1 node having the longest diameter (LDi) greater than (>) 1.5 centimeter (cm) or 1 extranodal lesion with LDi >1 cm (per the Lugano Criteria 2014). The Deauville 5-point scale (D5PS) score assessed on the FDG PET/CT should be between 3 to 5.
  • Not intended for or CAR-T cell therapy based on objective clinical criteria determined by the treating physician. Patients who cannot receive HSCT due to active disease are allowed on study (up to approximately 15 percent [%] of patients enrolled in each Phase). Documentation on lack of intention to proceed to receive HSCT or CAR-T therapy must be provided by the treating physician.
  • Adequate bone marrow function at screening, defined as:

    • (ANC) ≥1*10\^9 per liter (/L).
    • count ≥100*10\^9/L (without platelet transfusion less than [\<] 14 days prior to Cycle 1 Day 1 [C1D1]).
    • ≥8.5 gram per deciliter (g/dL) (without red blood cell transfusion \<14 days prior to C1D1).
  • Circulating lymphocytes less than or equal to (≤) 50*10\^9/L.
  • Adequate liver and kidney function, defined as:

    • (AST) or alanine transaminase (ALT) ≤2.5* (ULN), or ≤5*ULN in cases with known lymphoma involvement in the liver.
    • Serum total ≤2*ULN, or ≤5*ULN if due to Gilbert syndrome or in cases with known lymphoma involvement in the liver.
    • Calculated (CrCl) ≥30 milliliter per minute (mL/min) based on Cockcroft-Gault formula.
  • (ECOG) performance status of ≤2.
  • An estimated of >3 months at Screening.
  • Patients with primary refractory DLBCL defined as no response or relapse within 6 months after ending first-line treatment, will be allowed in the study.
  • Agree to highly effective during the duration of the study with contraception use continuing for 12 months after the last dose of study treatment
  • Female patients of must have a negative serum pregnancy test at Screening and agree to use highly effective methods of contraception throughout the study and for 12 months following the last dose of study treatment (except patients with Non-Childbearing potential: Age >50 years and naturally amenorrhoeic for >1 year, or previous bilateral salpingo-oophorectomy, or hysterectomy).
  • Male patients who are sexually active must use highly effective methods of contraception throughout the study and for 12 months following the last dose of study treatment. Male patients must agree not to donate sperm during the study treatment period and for 12 months following the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma, composite lymphoma (Hodgkin's lymphoma + non-Hodgkin's lymphoma [NHL]), DLBCL transformed from diseases other than indolent NHL; primary mediastinal (thymic) large B-cell lymphoma (PMBL); T-cell rich large B-cell lymphoma.
  • Previous treatment with selinexor or other XPO1 inhibitors.
  • to any drug contained in the combination therapy regimen (SR-GDP).
  • Known active central nervous system or meningeal involvement by DLBCL at time of Screening.
  • Use of any standard or experimental anti-DLBCL therapy (including nonpalliative radiation, chemotherapy, immunotherapy, radio-immunotherapy, or any other anticancer therapy) \<21 days prior to C1D1 (prednisone \<30 mg or equivalent is permitted; palliative radiation is permitted only if on non-target lesions).
  • Any AE, by C1D1, which has not recovered to Grade ≤1 ( [CTCAE], v.5.0), or returned to baseline, related to the previous DLBCL therapy, except hematological abnormalities (as specified in the inclusion criteria) and alopecia.
  • Major surgery \<14 days of Cycle 1 Day 1.
  • Hematopoietic stem cell transplantation/CAR-T therapy as follows:

    • stem cell transplant (SCT) \<100 days or allogeneic-SCT \<180 days prior to C1D1
    • Active (GVHD) after allogeneic SCT (or cannot discontinue GVHD treatment or prophylaxis)
    • CAR-T cell infusion \<90 days prior to Cycle 1
  • Neuropathy Grade ≥2 (CTCAE, v.5.0).
  • Any life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator's opinion, could compromise the patient's safety, or being compliant with the study procedures.
  • Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within 7 days prior to first dose of study treatment; however, prophylactic use of these agents is acceptable (including parenteral).
  • Patient with active virus (HBV), virus (HCV), or (HIV) infections:

    • Patient with active HBV are allowed if antiviral therapy for hepatitis B has been given for >8 weeks and viral load is \<100 International units (IU)/mL prior to first dose of study treatment.
    • Patients with known history of HCV or found to be HCV antibody positive on screening, are allowed if there is documentation of negative viral load per institutional standard.
    • Patients with HIV are allowed if they have a negative viral load per institutional standard, and no history of acquired immune deficiency syndrome (AIDS)-defining opportunistic infections in the last year.
  • Inability to swallow tablets, malabsorption syndrome, or any other gastrointestinal (GI) disease or dysfunction that could interfere with absorption of study treatment.
  • Breastfeeding or pregnant women.
  • Inability or unwillingness to sign an form (ICF).
  • In the opinion of the Investigator, patient who are significantly below their ideal body weight.
  • Patients who received a within prior 28 days of the first dose of study treatment.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
501 participants (estimated)

Study arms

  • Experimental
    Phase 2: Selinexor 40 mg + R-GDP

    Patients with RR DLBCL will receive combination therapy of selinexor 40 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally once weekly (QW) for each 28-day cycle until progressive disease (PD) or unacceptable toxicity.

    Drug: Selinexor (combination therapy) · Drug: Rituximab (combination therapy) · Drug: Gemcitabine (combination therapy) · Drug: Dexamethasone (combination therapy) · Drug: Cisplatin (combination therapy) · Drug: Selinexor (continuous therapy)

  • Experimental
    Phase 2: Selinexor 60 mg + R-GDP

    Patients with RR DLBCL will receive combination therapy of selinexor 60 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.

    Drug: Selinexor (combination therapy) · Drug: Rituximab (combination therapy) · Drug: Gemcitabine (combination therapy) · Drug: Dexamethasone (combination therapy) · Drug: Cisplatin (combination therapy) · Drug: Selinexor (continuous therapy)

  • Active comparator
    Phase 2: R-GDP

    Patients with RR DLBCL will receive R-GDP on specified days (Days 1, 2, 3, 4, and 8) for each 21-day cycle for up to 6 cycles.

    Drug: Rituximab (combination therapy) · Drug: Gemcitabine (combination therapy) · Drug: Dexamethasone (combination therapy) · Drug: Cisplatin (combination therapy)

  • Experimental
    Phase 3: Selinexor (Selected Dose) + R-GDP followed by Selinexor 60 mg

    Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.

    Drug: Selinexor (combination therapy) · Drug: Rituximab (combination therapy) · Drug: Gemcitabine (combination therapy) · Drug: Dexamethasone (combination therapy) · Drug: Cisplatin (combination therapy) · Drug: Selinexor (continuous therapy)

  • Experimental
    Phase 3: Selinexor (Selected Dose) + R-GDP followed by Placebo

    Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.

    Drug: Selinexor (combination therapy) · Drug: Rituximab (combination therapy) · Drug: Gemcitabine (combination therapy) · Drug: Dexamethasone (combination therapy) · Drug: Cisplatin (combination therapy) · Drug: Placebo matching for Selinexor (continuous therapy)

  • Placebo comparator
    Phase 3: Placebo + R-GDP followed by Placebo

    Patients with RR DLBCL will receive combination therapy of placebo matching for selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.

    Drug: Placebo matching for Selinexor (combination therapy) · Drug: Rituximab (combination therapy) · Drug: Gemcitabine (combination therapy) · Drug: Dexamethasone (combination therapy) · Drug: Cisplatin (combination therapy) · Drug: Placebo matching for Selinexor (continuous therapy)

Interventions

  • DrugSelinexor (combination therapy)

    Drug page: Selinexor

    Dose: 40 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral

  • DrugSelinexor (combination therapy)

    Drug page: Selinexor

    Dose: 60 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral

  • DrugSelinexor (combination therapy)

    Drug page: Selinexor

    Dose: Selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral

  • DrugPlacebo matching for Selinexor (combination therapy)

    Dose: Placebo matching for selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral

  • DrugRituximab (combination therapy)

    Drug page: Rituximab

    Dose: 375 milligram per meter square (mg/m\^2) on Day 1; Route of administration: intravenous (IV)

  • DrugRituximab (combination therapy)

    Drug page: Rituximab

    Dose: 375 mg/m\^2 on Day 1; Route of administration: IV

  • DrugGemcitabine (combination therapy)

    Drug page: Gemcitabine

    Dose: 1000 mg/m\^2 on Days 1 and 8; Route of administration: IV

  • DrugDexamethasone (combination therapy)

    Drug page: Dexamethasone

    Dose: 40 mg (20 mg if patient is more than 70 years old) on Days 1, 2, 3, and 4; Route of administration: oral or IV

  • DrugCisplatin (combination therapy)

    Drug page: Cisplatin

    Dose: 75 mg/m\^2 on Day 1; Route of administration: IV

  • Dose: 60 mg QW for each 28-day cycle until PD; Route of administration: oral

  • DrugPlacebo matching for Selinexor (continuous therapy)

    Dose: Placebo matching for 60 mg selinexor QW for each 28-day cycle until PD; Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Phase 2: Overall Response Rate (ORR): Based on Lugano Criteria 2014

    Time frame: From date of initial randomization to the date of disease progression or initiating a new DLBCL treatment (maximum of 5 years from randomization)

  2. Phase 3: Progression-free Survival (PFS): Based on Lugano Criteria 2014

    Time frame: From date of initial randomization to the date of disease progression or death (maximum of 5 years from randomization)

Secondary outcomes

  1. Phase 2: Progression-free Survival: Based on Lugano Criteria 2014

    Time frame: From date of initial randomization to the date of disease progression or death (maximum of 5 years from randomization)

  2. Phase 2: Overall Survival (OS)

    Time frame: From date of initial randomization until death (maximum of 5 years from randomization)

  3. Phase 3: Overall Response Rate: Based on Lugano Criteria 2014

    Time frame: From date of initial randomization to the date of disease progression or initiating a new DLBCL treatment (maximum of 5 years from randomization)

  4. Phase 3: Overall Survival

    Time frame: From date of initial randomization until death (maximum of 5 years from randomization)

  5. Phase 2: Overall Response Rate at the End of Combination Therapy (ORR-EoC): Based on Lugano Criteria 2014

    Time frame: From C1D1 (Cycles 1 up to 6; 21 days per cycle) up to 28 days after EoC therapy

  6. Phase 2: Overall Response Rate at the End of Combination Therapy: Based on Modified Lugano Criteria

    Time frame: From C1D1 (Cycles 1 up to 6; 21 days per cycle) up to 28 days after EoC therapy

  7. Phase 2: Duration of Response (DOR): Based on Lugano Criteria 2014

    Time frame: From time of first response until disease progression or death (maximum of 5 years from randomization)

  8. Phase 2: Number of Patients with Adverse Events (AEs)

    Time frame: Up to 30 days after last dose of study drug (maximum of 5 years from randomization)

  9. Phase 3: Overall Response Rate at the End of Combination Therapy: Based on Lugano Criteria 2014

    Time frame: From C1D1 (Cycles 1 up to 6; 21 days per cycle) up to 28 days after EoC therapy

  10. Phase 3: Overall Response Rate at the End of Combination Therapy: Based on Modified Lugano Criteria

    Time frame: From C1D1 (Cycles 1 up to 6; 21 days per cycle) up to 28 days after EoC therapy

  11. Phase 3: Duration of Response: Based on Lugano Criteria 2014

    Time frame: From time of first response until disease progression or death (maximum of 5 years from randomization)

  12. Phase 3: Progression-free Survival: Based on Modified Lugano Criteria

    Time frame: From date of initial randomization to the date of disease progression or death (maximum of 5 years from randomization)

  13. Phase 3: Number of Patients with Adverse Events

    Time frame: Up to 30 days after last dose of study drug (maximum of 5 years from randomization)

07

Study locations

38 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2020 (actual). Primary completion is estimated for Dec 2026, 75 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2020
First posted
Jun 22, 2020
StartActual
Sep 3, 2020
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Assuta Medical Center - Ramat Hachayal · Tel Aviv, Israel
Show 1 removed
  • Assuta medical centers - Ramat Hachayal · Tel Aviv, Israel
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    1 site added, 1 site removed
    Show site
    • Assuta Medical Center - Ramat Hachayal · Tel Aviv, Israel
    Show 1 removed
    • Assuta medical centers - Ramat Hachayal · Tel Aviv, Israel
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04442022
Responsible party
Sponsor
First posted
Jun 22, 2020
Start date
Sep 3, 2020
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion